About adaptive biotechnologies corp. - ADPT
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
ADPT At a Glance
Adaptive Biotechnologies Corp.
1165 Eastlake Avenue East
Seattle, Washington 98109
| Phone | 1-206-659-0067 | Revenue | 276.98M | |
| Industry | Biotechnology | Net Income | -59,499,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 54.772% | |
| Fiscal Year-end | 12 / 2026 | Employees | 624 | |
| View SEC Filings |
ADPT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 8.896 |
| Price to Book Ratio | 11.414 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -62.447 |
| Enterprise Value to Sales | 8.858 |
| Total Debt to Enterprise Value | 0.086 |
ADPT Efficiency
| Revenue/Employee | 443,871.795 |
| Income Per Employee | -95,350.962 |
| Receivables Turnover | 5.34 |
| Total Asset Turnover | 0.368 |
ADPT Liquidity
| Current Ratio | 3.339 |
| Quick Ratio | 3.229 |
| Cash Ratio | 2.524 |
ADPT Profitability
| Gross Margin | 70.029 |
| Operating Margin | -20.624 |
| Pretax Margin | -21.466 |
| Net Margin | -21.482 |
| Return on Assets | -7.915 |
| Return on Equity | -28.232 |
| Return on Total Capital | -13.864 |
| Return on Invested Capital | -14.34 |
ADPT Capital Structure
| Total Debt to Total Equity | 96.144 |
| Total Debt to Total Capital | 49.017 |
| Total Debt to Total Assets | 21.82 |
| Long-Term Debt to Equity | 89.945 |
| Long-Term Debt to Total Capital | 45.857 |